Indication
Know Medicine, Follow Guideline
Details coming soon
Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Primary Hyperlipidemia Age: Adult Condition: adjunct to diet, in combination with other low-density lipoprotein cholesterol lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible |
Dose: Tablet – bempedoic acid 180 mg/ezetimibe 10 mg Frequency: once daily |
|
Indication: Cardiovascular Risk Reduction Age: Adult Condition: unable to take recommended statin therapy with established cardiovascular disease, or a high risk for a cardiovascular disease event but without established cardiovascular disease |
Dose: Tablet – bempedoic acid 180 mg/ezetimibe 10 mg Frequency: once daily |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Form: Not specified – No approved pediatric dosage available Note: There is no approved pediatric dosage available for this medication. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment (Mild or moderate eGFR greater than or equal to 30 mL/min/1.73 m2) |
Dose: Not specified Note: No dosage adjustment is required |
|
Condition: Renal impairment (Severe eGFR less than 30 mL/min/1.73 m2) |
Dose: Not specified Note: Data are limited |
Administration
Administer one combination tablet containing 180 mg bempedoic acid and 10 mg ezetimibe orally once daily, either with or without food. The tablet must be swallowed whole and should not be crushed, cut, or chewed. If co-administered with bile acid sequestrants, this medication should be taken at least 2 hours before or at least 4 hours after the sequestrant. No dosage adjustment is necessary for patients with mild to moderate renal or hepatic impairment, though use in severe hepatic impairment is not recommended. Safety and efficacy have not been established in pediatric patients under 18 years of age. Periodic monitoring of serum uric acid and liver enzymes is advised.
Side Effect
- Upper respiratory tract infection (URTI) (4.5%)
- Muscle spasms (3.6%)
- Hyperuricemia (3.5%)
- Back pain (3.3%)
- Abdominal pain or discomfort (3.1%)
- Bronchitis (3%)
- Pain in extremity (3%)
- Anemia (2.8%)
- Elevated liver enzymes (2.1%)
- Gout (1.5%)
- Benign prostatic hyperplasia (1.3%)
- Atrial fibrillation (1.7%)
- Upper respiratory tract infection (URTI) (4.3%)
- Diarrhea (4.1%)
- Arthralgia (3%)
- Sinusitis (2.8%)
- Pain in extremity (2.7%)
- Fatigue (2.4%)
- Influenza (2%)
- Tendon rupture (0.5%)
Drug Interaction
Drug Interaction
Details coming soon
Disease Interaction
Disease Interaction
Details coming soon
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.